In the G465R-EGFR-SW48 (WT/G465R-EGFR-Heterozygote) xenograft model (Fig. 7e), cetuximab could not bind with EGFRG465R or affect EGFRG465R signaling, therefore the exogenous introduction of EGFR G465R in SW48 lowered the potency of cetuximab on tumor growth inhibition in the G465R-EGFR-SW48 (WT/G465R-EGFR-Heterozygote) model, in comparison to the SW48 (WT-EGFR) model. The gene discussed is EGFR; the disease is neoplasm.